Millennium Management Reduces $18M in ABIVAX Société Anonyme ($ABVX)

Millennium Management has trimmed its stake in ABIVAX Socie9te9 Anonyme (NasdaqGM: ABVX), cutting its holdings by 135,068 shares. The fund now holds 605,992 shares, valued at approximately $80.5 million, according to its latest Form 13F filing. This represents an 18.2% decrease from the previous quarter.

What Changed in Millennium Management's ABIVAX Position

Millennium Management reduced its position in ABIVAX Socie9te9 Anonyme by 18.2%, bringing its total holdings down to 605,992 shares from 741,060 shares. The value of these holdings is roughly $80.5 million as of the filing period.

Other Institutional Activity in ABIVAX Socie9te9 Anonyme

Other funds also adjusted their positions in ABIVAX. TCG Crossover Management, LLC cut 630,511 shares, ending with 6,481,085 shares valued at about $721.7 million. UBS Group AG increased its position by 123,500 shares, holding 4,547,406 shares worth approximately $506.4 million. Darwin Global Management, Ltd. added 290,156 shares, now holding 3,468,657 shares valued at $352.1 million. Meanwhile, Morgan Stanley reduced its stake by 1,447,036 shares, leaving it with 1,704,958 shares valued at $189.8 million.

ABIVAX Société Anonyme Stock Up 17.2%

Shares of ABIVAX Socie9te9 Anonyme traded near $132.83 on Wednesday. The company has a market cap of $10.63 billion and a forward P/E ratio of -40.75, indicating it is not currently profitable. Its beta is -0.2, suggesting it is less volatile than the market. The stock's 52-week range is between $7.41 and $148.83, with a 50-day moving average of $111.05 and a 200-day moving average of $111.25. The company's current ratio stands at 8.25, with a quick ratio of 8.07 and a debt-to-equity ratio of 7.96.

Recent Earnings

ABIVAX reported revenue of $4.92 million with a growth rate of 35.2%. The company is not currently profitable, with a net margin of 0% and a return on equity of -157.1%. The next earnings report is expected on September 21, 2026.

Insider Buying and Selling at ABIVAX Société Anonyme

Recent insider activity includes Sofinnova Crossover selling 1,000,000 shares at $133.70 on January 8, 2026. Earlier, on October 28, 2025, Sofinnova Crossover SLP sold 1,200,000 shares at $92.75.

Analysts Set New Price Targets

On June 30, 2026, Jefferies upgraded ABIVAX to a 'buy' rating with a price target of $158. Leerink Partners and BTIG maintained their 'buy' ratings with targets of $148 and $175, respectively. The consensus among 11 analysts is a 'buy' recommendation, with a mean price target of $150.73.

About ABIVAX Socie9te9 Anonyme

ABIVAX Socie9te9 Anonyme is a biotechnology company based in Paris, France. It focuses on developing treatments that leverage the body's immune system to combat chronic inflammatory diseases. Its lead drug candidate, obefazimod, is in advanced clinical trials for ulcerative colitis and Crohn's disease. Founded in 2013, the company employs about 80 people under the leadership of CEO Marc de Garidel.

Bottom Line

Millennium Management's decision to reduce its stake in ABIVAX by 18.2% reflects its current investment strategy. Investors often watch such filings to gauge fund managers' confidence in a company. Remember, these 13F filings are backward-looking and may not represent the fund's current position. ABIVAX's ongoing clinical trials and analyst ratings remain key points of interest for investors.